Peter Matthew De Blank

Dr. Peter Matthew De Blank

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2014 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
QOQuinn T. Ostrom
Quinn T. Ostrom
PBPeter Matthew De Blank
Peter Matthew De Blank
CKCarol Kruchko
Carol Kruchko
CPClaire M. Petersen
Claire M. Petersen
PLPeter Liao
Peter Liao
JIll S Barnholt-SloanJIll S Barnholt-Sloan
JIll S Barnholt-Sloan
The CBTRUS Statistical Report: Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007–2011 comprehensively describes the current population-based incidence of primary malignant and non-malignant brain and CNS tumors in children ages 0–14 years, collected and reported by central cancer registries covering approximately 99.8% of the United States population (for 2011 only, data were available for 50 out of 51 registries). Overall, brain and CNS tumors are the most common solid tumor, the most common cancer, and the most common cause of cancer death in infants and children 0–14 years. This report aims to serve as a useful resource for researchers, clinicians, patients, and families.

22 December 2015 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
QOQuinn T. Ostrom
Quinn T. Ostrom
HGHaley Gittleman
Haley Gittleman
PBPeter Matthew De Blank
Peter Matthew De Blank
JFJonathan L. Finlay
Jonathan L. Finlay
JGJames G. Gurney
James G. Gurney
JIll S Barnholt-SloanJIll S Barnholt-Sloan
JIll S Barnholt-Sloan
Brain and central nervous system (CNS) tumors found in adolescents and young adults (AYA) are a distinct group of tumors that pose challenges not only to treatment but also to reporting. Overall, cancer that occurs in this age group is biologically distinct from those that occur in both younger and older age groups1,2 posing significant challenges for clinicians. The most commonly diagnosed histologies in AYA vary from those in both children age (0-14 years), and older adults (40+ years).3,4 Prognosis and expected survival also varies between younger and older adults, with those who are diagnosed with brain and CNS tumors at younger ages having significantly longer survival. Despite this survival advantage, recent analyses have reported that while cancer survival has been improving overall, AYA have not experienced these same increases in survival and in some cases may have worse survival than those cancers diagnosed in persons over age 40 years.5 This report provides an in depth analyses of the epidemiology of brain and CNS tumors in adolescents and young adults in the United States (US), and is the first report to provide histology-specific statistics in this population for both malignant and non-malignant brain and other CNS tumors.

1 February 2019 in Current Opinion in Pediatrics
Verified
Journal Article
Closed access
PBPeter Matthew De Blank
Peter Matthew De Blank
PBPratiti Bandopadhayay
Pratiti Bandopadhayay
DHDaphne Haas-Kogan
Daphne Haas-Kogan
MFMaryam Fouladi
Maryam Fouladi
JFJason Fangusaro
Jason Fangusaro
Purpose of review: Pediatric low-grade gliomas (pLGGs) have been treated with similar therapies for the last 30 years. Recent biological insights have allowed a new generation of targeted therapies to be developed for these diverse tumors. At the same time, technological advances may redefine the late toxicities associated with radiation therapy. Understanding recent developments in pLGG therapy is essential to the management of these common pediatric tumors. Recent findings: It is now well understood that aberrations of the mitogen-activated protein kinase pathway are key to oncogenesis in low-grade gliomas. This understanding, along with the development of available targeted agents, have heralded a new era of understanding and treatment for these patients. Promising, sustained responses are now being seen in early phase trials among patients with multiply recurrent/progressive disease. Also, newer and highly conformal radiation approaches such as proton beam radiotherapy maintain efficacy of radiation but limit radiation-associated toxicities. Summary: Novel therapies offer the potential for tumor control with greatly reduced toxicities. However, late effects of these therapies are just now being explored. Improved radiation approaches and targeted agents have the potential to redefine traditional therapy for pLGG.

1 September 2017 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Closed access
PBPeter Matthew De Blank
Peter Matthew De Blank
MFMichael J. Fisher
Michael J. Fisher
GLGrant T. Liu
Grant T. Liu
DGDavid H. Gutmann
David H. Gutmann
RLRobert Listernick
Robert Listernick
RARobert A. Do Avery
Robert A. Do Avery
Optic pathway gliomas (OPGs) occur in 15%–20% of children with neurofibromatosis type 1 (NF1), leading to visual deficits in fewer than half of these individuals. The goal of chemotherapy is to preserve vision, but vision loss in NF1-associated OPG can be unpredictable. Determining which child would benefit from chemotherapy and, equally important, which child is better observed without treatment can be difficult. Unfortunately, despite frequent imaging and ophthalmologic evaluations, some children experience progressive vision loss before treatment. Indications for chemotherapy usually are based on a comprehensive, quantitative assessment of vision, but reliable vision evaluation can be challenging in young children with NF1-OPG. The ability to identify and predict impending vision loss could potentially improve management decisions and visual outcomes. To address this challenge, ophthalmologic, electrophysiologic, and imaging biomarkers of vision in NF1-OPG have been proposed. We review current recommendations for the surveillance of children at risk for NF1-OPG, outline guidelines for initiating therapy, and describe the utility of proposed biomarkers for vision.

20 May 2014 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
QOQuinn T. Ostrom
Quinn T. Ostrom
YCYanwen Chen
Yanwen Chen
PBPeter Matthew De Blank
Peter Matthew De Blank
AOAnnie Ondracek
Annie Ondracek
PFPaul Farah
Paul Farah
JIll S Barnholt-SloanJIll S Barnholt-Sloan
JIll S Barnholt-Sloan
Background Atypical teratoid/rhabdoid tumor is a rare malignant CNS tumor that most often affects children ≤3 years old. The Central Brain Tumor Registry of the United States contains the largest aggregation of population-based incidence data for primary CNS tumors in the US. Its data were used to describe the incidence, associated trends, and relative survival after diagnosis of atypical teratoid/rhabdoid tumor. Methods Using data from 50 cancer registries between 2001 and 2010, age-adjusted incidence rates per 100 000 and 95% CIs were calculated by sex, race, Hispanic ethnicity, age at diagnosis, and location of tumor in the CNS for children aged 0 to 19 years. Relative survival rates and 95% CIs were also calculated. Results The average annual age-adjusted incidence rate was 0.07 (95% CI: 0.07, 0.08). Incidence rates did not significantly vary by sex, race, or ethnicity. Age had a strong effect on incidence rate, with highest incidence among children <1 year, and decreasing incidence with increasing age. The 6-month, 1-year, and 5-year relative survival rates for all ages were 65.0%, 46.8%, and 28.3%, respectively. Atypical teratoid/rhabdoid tumor can occur anywhere in the CNS, but supratentorial tumors were more common with increasing age. Conclusion We confirm differences in survival by age at diagnosis, treatment pattern, and location of tumor in the brain. This contributes to our understanding of these tumors and may stimulate research leading to improved treatment of this devastating childhood disease.

25 August 2014 in Cancer
Verified
Journal Article
Open access
PDF file
HGHaley R. Gittleman
Haley R. Gittleman
QOQuinn T. Ostrom
Quinn T. Ostrom
CRChaturia D. Rouse
Chaturia D. Rouse
JDJacqueline A. Dowling
Jacqueline A. Dowling
PBPeter Matthew De Blank
Peter Matthew De Blank
JIll S Barnholt-SloanJIll S Barnholt-Sloan
JIll S Barnholt-Sloan
BACKGROUND: Time trends in cancer incidence rates (IR) are important to measure the changing burden of cancer on a population over time. The overall IR of cancer in the United States is declining. Although central nervous system tumors (CNST) are rare, they contribute disproportionately to mortality and morbidity. In this analysis, the authors examined trends in the incidence of the most common cancers and CNST between 2000 and 2010.METHODS: The current analysis used data from the United States Cancer Statistics publication and the Central Brain Tumor Registry of the United States. Age‐adjusted IR per 100,000 population with 95% confidence intervals and the annual percent change (APC) with 95% confidence intervals were calculated for selected common cancers and CNST overall and by age, sex, race/ethnicity, selected histologies, and malignancy status.RESULTS: In adults, there were significant decreases in colon (2000‐2010: APC, −3.1), breast (2000‐2010: APC, −0.8), lung (2000‐2010: APC, −1.1), and prostate (2000‐2010: APC, −2.4) cancer as well as malignant CNST (2008‐2010: APC, −3.1), but a significant increase was noted in nonmalignant CNST (2004‐2010: APC, 2.7). In adolescents, there were significant increases in malignant CNST (2000‐2008: APC, 1.0) and nonmalignant CNST (2004‐2010: APC, 3.9). In children, there were significant increases in acute lymphocytic leukemia (2000‐2010: APC, 1.0), non‐Hodgkin lymphoma (2000‐2010: APC, 0.6), and malignant CNST (2000‐2010: APC, 0.6).CONCLUSIONS: Surveillance of IR trends is an important way to measure the changing public health and economic burden of cancer. In the current study, there were significant decreases noted in the incidence of adult cancer, whereas adolescent and childhood cancer IR were either stable or increasing. Cancer 2015;121:102–112. © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.